Literature DB >> 22135078

Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.

Takayoshi Tachibana, Masatsugu Tanaka, Hirotaka Takasaki, Ayumi Numata, Shin Fujisawa, Atsuo Maruta, Hiroshi Harada, Hiraku Mori, Yoshiaki Ishigatsubo, Heiwa Kanamori.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22135078     DOI： 10.1007/s12185-011-0967-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Authors:  Richard A Larson; Eric L Sievers; Edward A Stadtmauer; Bob Löwenberg; Elihu H Estey; Hervé Dombret; Matthias Theobald; Dimitris Voliotis; John M Bennett; Maria Richie; Lance H Leopold; Mark S Berger; Matthew L Sherman; Michael R Loken; Jacques J M van Dongen; Irwin D Bernstein; Frederick R Appelbaum
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

2.  Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.

Authors:  H Tamai; Y Shioi; H Yamaguchi; M Okabe; S Wakita; T Mizuki; K Nakayama; K Inokuchi; K Tajika; K Dan
Journal:  Leukemia       Date:  2007-11-08       Impact factor: 11.528

Review 3.  Management of relapse after allo-SCT for AML and the role of second transplantation.

Authors:  B N Savani; S Mielke; N Reddy; S Goodman; M Jagasia; K Rezvani
Journal:  Bone Marrow Transplant       Date:  2009-10-26       Impact factor: 5.483

4.  Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.

Authors:  Toshihiko Ando; Noriyuki Mitani; Kimie Matsunaga; Tatsuki Nakazora; Toshikazu Gondo; Toshiaki Yujiri; Yukio Tanizawa
Journal:  Tohoku J Exp Med       Date:  2010-02       Impact factor: 1.848

Review 5.  ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?

Authors:  Monica S Thakar; Stephen J Forman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

6.  Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.

Authors:  Masahiko Sumi; Naoaki Ichikawa; Kentaro Nasu; Ikuo Shimizu; Toshimitsu Ueki; Mayumi Ueno; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2009-11-11       Impact factor: 2.490

7.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

8.  Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.

Authors:  Marco Mielcarek; Barry E Storer; Mary E D Flowers; Rainer Storb; Brenda M Sandmaier; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-03       Impact factor: 5.742

9.  Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.

Authors:  Taofeek Owonikoko; Mounzer Agha; Ronald Balassanian; Ryan Smith; Anastasios Raptis
Journal:  Nat Clin Pract Oncol       Date:  2007-08

10.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Authors:  U Platzbecker; M Wermke; J Radke; U Oelschlaegel; F Seltmann; A Kiani; I-M Klut; H Knoth; C Röllig; J Schetelig; B Mohr; X Graehlert; G Ehninger; M Bornhäuser; C Thiede
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.